China Life Private Equity Investment
China Life Private Equity Investment is a principal investment firm that focus on investments in infrastructure, construction, culture and media.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed China Life Private Equity Investment Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
China Life Private Equity Investment is a principal investment firm that focus on investments in infrastructure, construction, culture and media.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2022 | Doma Biopharmaceutical | Series A | 0 |
| 5/2021 | GeneQuantum Healthcare | Series C | - |
| 12/2022 | MAXVAX | Series B | 43M |
| 4/2022 | METiS Therapeutics | Series B | 0 |
| 8/2018 | Harbour Biomed | Series B | 0 |
| 12/2022 | Fushoukang | Series C | 14.3M |
| 11/2021 | Immunochina | Series D | - |
| 6/2022 | Hanbang Technology | Series C | 0 |
| 6/2018 | Wanka Online | Series C | 0 |
| 7/2022 | MAXVAX | Series B | 0 |
| 9/2013 | Asia Bioenergy Technologies Berhad | Venture Round | 1.6M |
| 3/2020 | OPM Biosciences | Corporate Round | 14.4M |
| 10/2021 | SinoTau | Series D | 0 |
| 7/2022 | MAXVAX | Series B | 0 |
| 6/2022 | Hanbang Technology | Series C | 0 |
| 6/2022 | Doma Biopharmaceutical | Series A | 0 |
| 4/2022 | METiS Therapeutics | Series B | 0 |
| 11/2021 | Immunochina | Series D | - |
| 10/2021 | SinoTau | Series D | 0 |
| 5/2021 | GeneQuantum Healthcare | Series C | - |
| 3/2020 | OPM Biosciences | Corporate Round | 0 |
| 8/2018 | Harbour Biomed | Series B | 0 |
| 6/2018 | Wanka Online | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
